Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

H.B. Fuller Company

FUL
Materials · Specialty Chemicals

H.B. Fuller Company is coiled. The quarters are improving, yet the P/E sits at the 3rd percentile of its own 4-year range — the business is moving before the market.

Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.

The price is building a base (6 weeks in) while the P/E sits at the 3rd percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +75.0% year on year, and 224% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.

Stage
Improving
fundamental trajectory, 12 quarters
Price
$58.9
+5.9% 1Y
P/E
17.5×
3rd pctile
of its own 4-year range
Revenue (May 26)
$0.9 B
+5.6% YoY
Profit (May 26)
$0.1 B
+75.0% YoY
Operating margin
12.6%
+1.5 pp YoY
ROE
9%
FY25
ROIC
7.6%
vs WACC 7.2% → +0.4 pp
Cash conversion
224%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

H.B. Fuller Company trades at $58.9, building a base and 6 weeks into that stage. That is −2.0% against its own 200-day average. It sits at 53% of a 52-week range of $49 to $67. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (7 weeks and counting).

Today the stock is building a base — week 6 of stage 1. At $58.9 it trades −2.0% versus its 200-day average and sits at 53% of its 52-week range ($49–$67).

Aug 26: $58.9 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−2.0% versus the 200-day line, week 6 of stage 1
Price50-day avg200-day avg
S2S2S1S4S3$88.6$78.0$67.5$56.9$46.4$$59$60Jul 23Apr 24Jan 25Oct 25Aug 26
S2S2S1S4S3$88.6$78.0$67.5$56.9$46.4$$59$60Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +32% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (7 weeks and counting; last ahead the week of 2026-06-18) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

H.B. Fuller Company trades at 17.5× P/E, near the bottom of its own range — cheaper only 3% of the time. Its long-run median P/E is 25.0×, measured across 4.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 17.5× is near the bottom of its own range — cheaper only 3% of the time, against a long-run median of 25.0× measured over 4.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

P/E 17.5× vs a 25.0× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.2-year window; loss-period spikes above 33× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 3% of the time
P/EMedianEPS (TTM) (quarterly)
34.3×$3.629.5×$2.724.7×$1.819.9×$0.915.1×$0.0×$17.48×$3Jun 22Jun 23Jul 24Jul 25Aug 26
34.3×$3.629.5×$2.724.7×$1.819.9×$0.915.1×$0.0×$17.48×$3Jun 22Jul 24Aug 26
PEG 0.84 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 19 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
2.0×1.7×1.4×1.1×0.7××0.84×Nov 21Dec 22Mar 24Mar 25May 26
2.0×1.7×1.4×1.1×0.7××0.84×Nov 21Mar 24May 26
P/E
17.5×
3rd percentile of 4y
PEG
0.60
as reported

Why the multiple sits where it does: over the past year annual EPS moved +19.6% against a +5.9% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the −6.6%/yr price move, ~+6.0%/yr came from earnings growth and ~−12.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Improving

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

H.B. Fuller Company reads as improving on its fundamental arc. Improving — profit growth bottomed 3 quarters ago at −41.2% and has held its recovery at +90.0%, ROCE holding at 8.5%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue −2.8% in FY25, profit +15.4% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
16%23%10.0%11%4.0%−1.3%−2.1%−13%−8.1%−26%%%−2.8%15.4%FY21FY23FY25
16%23%10.0%11%4.0%−1.3%−2.1%−13%−8.1%−26%%%−2.8%15.4%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit accelerating
RevenueProfitEPS
2.3%101%0.0%62%−2.4%24%−4.7%−14%−7.0%−53%%%−0.8%90%82.2%Sep 23Nov 24May 26
2.3%101%0.0%62%−2.4%24%−4.7%−14%−7.0%−53%%%−0.8%90%82.2%Sep 23Nov 24May 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
9.2%8.8%8.3%7.9%7.5%%8.5%Sep 23Mar 24Nov 24Aug 25May 26
9.2%8.8%8.3%7.9%7.5%%8.5%Sep 23Nov 24May 26
Revenue growth
Stuck low
latest −0.8% · span −6.4% to +1.7%
Profit growth
Flat
latest +90.0% · span −42.1% to +90.0%
EPS growth
Flat
latest +82.2% · span −36.9% to +82.2%
ROCE
Stuck low
latest 8.5% · span 7.6%–9.1%

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue−2.8%−2.6%
Profit+15.4%−5.9%
EPS+19.6%−5.5%
Stock price+5.9%−6.6%−2.1%+2.3%
Revenue YoY (May 26)
+5.6%
latest quarter vs a year ago
Profit YoY (May 26)
+75.0%
latest quarter vs a year ago
Revenue 10y
1.4%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

53.0/100 — rank 9 of 29 in Specialty Chemicals · 85% evidence confidence

H.B. Fuller Company scores 53.0 out of 100 against the 29 companies it is compared with in Specialty Chemicals, ranking 9. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 22.1 + 10.9 + 16.1 + 3.9 = 53. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

H.B. Fuller Company reported $0.9 B of revenue in the May 26 quarter, +5.6% year on year. Over 4 years it has compounded at 1.4% a year. The last full year, FY25, came in at $3.5 B. The last four reported quarters add to $3.5 B.

FY25 revenue came in at $3.5 B (−2.8% on the year), capping 4 years at 1.4% compound. The latest quarter (May 26) printed $0.9 B, +5.6% year on year.

FY25 revenue $3.5 B (−2.8% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
1.4% a year over 4 years
RevenueYoY growth
4.016%3.010.0%2.04.0%1.0−2.1%0.0−8.1%$ B%$4B−2.8%FY21FY23FY25
4.016%3.010.0%2.04.0%1.0−2.1%0.0−8.1%$ B%$4B−2.8%FY21FY23FY25
May 26: $0.9 B (+5.6% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
1.06.5%0.83.1%0.5−0.3%0.3−3.7%0.0−7.1%$ B%$1B5.6%Sep 23Nov 24May 26
1.06.5%0.83.1%0.5−0.3%0.3−3.7%0.0−7.1%$ B%$1B5.6%Sep 23Nov 24May 26

Pace check: the last four quarters averaged −0.9% growth against the decade's 1.4% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −0.8% over the last 4 quarters against −0.4%/yr over the last 8 — stabilising; TTM profit +90.0% vs +5.7%/yr — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

H.B. Fuller Company's operating margin is 12.6% in the May 26 quarter, +1.5 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 7.6% to 10.4%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 12.6%, +1.5 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 7.6%–10.4%, and FY25's 10.4% is the top of that band — a record year.

Why the margin moved: operating margin went +1.5 pp year on year while gross margin went +1.5 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 10.4% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a 7.6–10.4% band over 5 years
operating marginYoY change (pp)
11%2.0%9.8%1.3%9.0%0.6%8.2%0.0%7.4%−0.7%%%10.4%0.6%FY21FY23FY25
11%2.0%9.8%1.3%9.0%0.6%8.2%0.0%7.4%−0.7%%%10.4%0.6%FY21FY23FY25
May 26: 12.6% operating margin (+1.5 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
13%3.3%11%1.5%9.4%−0.4%7.6%−2.2%5.8%−4.0%%%12.6%1.5%Sep 23Nov 24May 26
13%3.3%11%1.5%9.4%−0.4%7.6%−2.2%5.8%−4.0%%%12.6%1.5%Sep 23Nov 24May 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

H.B. Fuller Company earned $0.1 B of net profit in the May 26 quarter, +75.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $0.1 B. The 4-year compound rate is −1.6%. That is 7.4% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.

May 26 profit was $0.1 B, +75.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $0.1 B (+15.4%), and the 4-year compound rate is −1.6%.

FY25 profit $0.1 B (+15.4% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
−1.6% a year over 4 years
Net profitYoY growth
0.1918%0.157.5%0.10−3.4%0.05−14%0.00−25%$ B%$0B15.4%FY21FY23FY25
0.1918%0.157.5%0.10−3.4%0.05−14%0.00−25%$ B%$0B15.4%FY21FY23FY25
May 26: $0.1 B (+75.0% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Net profit (quarterly)YoY growth
0.08118%0.0554%0.03−10%0.01−74%−0.02−138%$ B%$0B75%Sep 23Nov 24May 26
0.08118%0.0554%0.03−10%0.01−74%−0.02−138%$ B%$0B75%Sep 23Nov 24May 26

Why profit moved: revenue contributed +5.6% and the margin +1.5 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +63.9% vs revenue −0.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 224% of H.B. Fuller Company's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.1 B of profit. After $0.1 B of capital spending, $0.1 B was left as free cash.

FY25: operating cash of $0.3 B against reported profit of $0.1 B, leaving free cash of $0.1 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 224% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.3 B vs profit $0.1 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
224% of 3-year profit arrived as cash
Operating cashNet profitFree cash
0.40.30.20.10.0$ B$0B$0B$0BFY21FY23FY25
0.40.30.20.10.0$ B$0B$0B$0BFY21FY23FY25
May 26: operating cash $0.1 B = 171% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.18436%0.12185%0.06−67%−0.01−318%−0.07−569%$ B%$0B171%Sep 23Nov 24May 26
0.18436%0.12185%0.06−67%−0.01−318%−0.07−569%$ B%$0B171%Sep 23Nov 24May 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

H.B. Fuller Company does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.1 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.150.110.080.040.00$ B$0BFY21FY23FY25
0.150.110.080.040.00$ B$0BFY21FY23FY25
May 26: capex $0.1 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.060.170.050.100.030.030.02−0.040.00−0.11$ B$ B$0B$0BSep 23Nov 24May 26
0.060.170.050.100.030.030.02−0.040.00−0.11$ B$ B$0B$0BSep 23Nov 24May 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

H.B. Fuller Company earns a ROE of 8% in FY25. That is up from a trough of 7% in FY24. Return on invested capital clears the cost of that capital by +0.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 4.3% net margin on 0.67× asset turns.

FY25 ROE is 8%, recovered from a FY24 trough of 7% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 4.3% net margin × 0.67× asset turns × 2.59× balance-sheet leverage ≈ 7.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 7.6% − 7.2% = a +0.4 pp spread. The 7.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 8% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 7.2% cost of capital used on this page.
the climb back from FY24's 7%
ROEROIC (annual)WACC
12%10%8.6%7.0%5.5%%7.5%6.5%FY21FY23FY25
12%10%8.6%7.0%5.5%%7.5%6.5%FY21FY23FY25
May 26: ROIC 7.2% (TTM) vs WACC 7.2% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
13%4.4%−4.3%−13%−21%%7.2%9.6%Sep 23Nov 24May 26
13%4.4%−4.3%−13%−21%%7.2%9.6%Sep 23Nov 24May 26
11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

H.B. Fuller Company paid $0.95 per share over the last four reported quarters, up 4.3% on a year ago. The most recent declaration was $0.24 for May 26. Against the current price of $58.9 that is a trailing yield of 1.61%, measured on dividends already paid rather than on a forecast.

H.B. Fuller Company paid $0.95 per share across the last four reported quarters, most recently $0.24 for May 26. That is up 4.3% against the same quarter a year earlier. Against the current price of $58.9 the trailing twelve months work out to 1.61% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $0.24 (May 26)
Dividend per share
0.260.200.130.070.00$ B$0BSep 23Mar 24Nov 24Aug 25May 26
0.260.200.130.070.00$ B$0BSep 23Nov 24May 26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

H.B. Fuller Company carries total debt of $2.1 B against shareholder equity of $2.1 B as of May 26, a debt-to-equity of 1.00. On the annual view that ratio went from 1.01 in FY21 to 1.01 in FY25. Read the returns elsewhere on this page with that leverage in mind.

May 26: total debt of $2.1 B against shareholder equity of $2.1 B — a debt-to-equity of 1.00. On the annual view, debt-to-equity went from 1.01 (FY21) to 1.01 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $2.0 B at 1.01× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
2.21.11×1.61.08×1.11.06×0.51.03×0.01.00×$ B×$2B1.01×FY21FY23FY25
2.21.11×1.61.08×1.11.06×0.51.03×0.01.00×$ B×$2B1.01×FY21FY23FY25
May 26: debt $2.1 B, debt-to-equity 1.00 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
2.41.24×1.81.17×1.21.11×0.61.05×0.00.98×$ B×$2B1.00×Sep 23Nov 24May 26
2.41.24×1.81.17×1.21.11×0.61.05×0.00.98×$ B×$2B1.00×Sep 23Nov 24May 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

4.5% of H.B. Fuller Company's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 4.5% of the float is sold short, and at typical trading volumes it would take about 2.3 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
4.5%
of the tradable float
Days to cover
2.3
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

H.B. Fuller Company: the Z-score reads 2.21. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.21 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.21.

15 · Related companies · Specialty Chemicals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1NewMarket CorporationNEU 61.9/100Thin evidence · provisional58% evidence BREAKING OUT 16.9/35 Revenue — · PAT — · OPM change -1.4 pp 45% evidence 16.1/25 ROCE 5.5% · OPM 21.4% 76% evidence 11.4/20 P/E 17× · PEG — 15% evidence 17.5/20 RS sector 5.4% · RS bench 8.6% · 1Y 20.4%12 of 12 weeks ahead 100% evidence
Exact sum: 16.9 + 16.1 + 11.4 + 17.5 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
2Sociedad Química y Minera de Chile S.A.SQM 61.7/100Mixed-positive evidence81% evidence ASLEEP 28.8/35 Revenue 18.3% · PAT 48.4% · OPM change 17.4 pp 83% evidence 15.8/25 ROCE 6.3% · OPM 41% 76% evidence 15.1/20 P/E 28.4× · PEG 0.81 65% evidence 2.0/20 RS sector -9.7% · RS bench -8.3% · 1Y 62.4%0 of 12 weeks ahead 100% evidence
Exact sum: 28.8 + 15.8 + 15.1 + 2 = 61.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.7% and the one-year return is 62.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3WD-40 CompanyWDFC 61.3/100Thin evidence · provisional58% evidence TURNING 21.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence 17.4/25 ROCE 10.8% · OPM 16.3% 76% evidence 10.2/20 P/E 30.4× · PEG — 15% evidence 12.4/20 RS sector -3.7% · RS bench -1.4% · 1Y 7.5%5 of 12 weeks ahead 100% evidence
Exact sum: 21.3 + 17.4 + 10.2 + 12.4 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Sensient Technologies CorporationSXT 60.7/100Thin evidence · provisional58% evidence FADING 20.4/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence 12.8/25 ROCE 3.8% · OPM 15.3% 76% evidence 9.8/20 P/E 33.2× · PEG — 15% evidence 17.7/20 RS sector 7.9% · RS bench 10.5% · 1Y 9%8 of 12 weeks ahead 100% evidence
Exact sum: 20.4 + 12.8 + 9.8 + 17.7 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5Quaker Chemical CorporationKWR 57.5/100Thin evidence · provisional58% evidence BREAKING OUT 21.5/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence 8.3/25 ROCE 1.7% · OPM 7% 76% evidence 10.5/20 P/E 28.3× · PEG — 15% evidence 17.2/20 RS sector 6% · RS bench 8.7% · 1Y 36.6%7 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 8.3 + 10.5 + 17.2 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Axalta Coating Systems Ltd.AXTA 56.2/100Thin evidence · provisional58% evidence BREAKING OUT 15.3/35 Revenue — · PAT — · OPM change -2.3 pp 45% evidence 11.7/25 ROCE 2.8% · OPM 11.6% 76% evidence 10.8/20 P/E 21.1× · PEG — 15% evidence 18.4/20 RS sector 6.4% · RS bench 9.2% · 1Y 32.5%7 of 12 weeks ahead 100% evidence
Exact sum: 15.3 + 11.7 + 10.8 + 18.4 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Ashland Inc.ASH 54.2/100Thin evidence · provisional58% evidence BREAKING OUT 18.8/35 Revenue — · PAT — · OPM change -2.5 pp 45% evidence 7.0/25 ROCE 1% · OPM 8.1% 76% evidence 8.9/20 P/E 57.8× · PEG — 15% evidence 19.5/20 RS sector 10.3% · RS bench 12.9% · 1Y 39%9 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 7 + 8.9 + 19.5 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8The Sherwin-Williams CompanySHW 53.8/100Thin evidence · provisional58% evidence TURNING 18.7/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence 15.5/25 ROCE 7.1% · OPM 14.2% 76% evidence 10.0/20 P/E 31.7× · PEG — 15% evidence 9.6/20 RS sector -6.6% · RS bench -4% · 1Y 2.7%1 of 12 weeks ahead 100% evidence
Exact sum: 18.7 + 15.5 + 10 + 9.6 = 53.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9H.B. Fuller Companythis pageFUL 53.0/100Mixed-positive evidence85% evidence BASING 22.1/35 Revenue -0.6% · PAT 80.6% · OPM change 1.2 pp 95% evidence 10.9/25 ROCE 2.6% · OPM 12.3% 76% evidence 16.1/20 P/E 19× · PEG 0.5 65% evidence 3.9/20 RS sector -14.3% · RS bench -12.2% · 1Y 4.8%2 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 10.9 + 16.1 + 3.9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10International Flavors & Fragrances Inc.IFF 52.4/100Mixed-positive evidence64% evidence ASLEEP 21.5/35 Revenue -5.6% · PAT — · OPM change 41.8 pp 62% evidence 7.2/25 ROCE 1.2% · OPM 10% 76% evidence 10.6/20 P/E 22.2× · PEG — 15% evidence 13.1/20 RS sector 0% · RS bench 2.2% · 1Y 27.3%1 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 7.2 + 10.6 + 13.1 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Eastman Chemical CompanyEMN 52.4/100Thin evidence · provisional58% evidence ASLEEP 18.6/35 Revenue — · PAT — · OPM change -4.6 pp 45% evidence 13.3/25 ROCE 4.8% · OPM 8.6% 76% evidence 11.2/20 P/E 17.4× · PEG — 15% evidence 9.3/20 RS sector -5.5% · RS bench -3.5% · 1Y 19.9%0 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 13.3 + 11.2 + 9.3 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Avient CorporationAVNT 52.2/100Mixed-positive evidence64% evidence ASLEEP 21.8/35 Revenue 1.3% · PAT 56.9% · OPM change 11.2 pp 62% evidence 9.1/25 ROCE 1.9% · OPM 11.3% 76% evidence 10.9/20 P/E 21.1× · PEG — 15% evidence 10.4/20 RS sector -4.6% · RS bench -2.6% · 1Y 16.2%0 of 12 weeks ahead 100% evidence
Exact sum: 21.8 + 9.1 + 10.9 + 10.4 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Balchem CorporationBCPC 52.2/100Thin evidence · provisional58% evidence TURNING 18.6/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 14.6/25 ROCE 3.8% · OPM 20.5% 76% evidence 9.9/20 P/E 33.2× · PEG — 15% evidence 9.1/20 RS sector -5.8% · RS bench -3.6% · 1Y 9.7%0 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 14.6 + 9.9 + 9.1 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14RPM International Inc.RPM 50.2/100Thin evidence · provisional58% evidence TURNING 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence 12.7/25 ROCE 4.8% · OPM 5% 76% evidence 11.0/20 P/E 20.5× · PEG — 15% evidence 8.2/20 RS sector -8.3% · RS bench -5.8% · 1Y -3.8%1 of 12 weeks ahead 100% evidence
Exact sum: 18.3 + 12.7 + 11 + 8.2 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15PPG Industries, Inc.PPG 50.2/100Thin evidence · provisional58% evidence TURNING 16.8/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence 12.8/25 ROCE 3.6% · OPM 13.8% 76% evidence 11.3/20 P/E 17.4× · PEG — 15% evidence 9.3/20 RS sector -5.7% · RS bench -3.5% · 1Y 10.1%3 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 12.8 + 11.3 + 9.3 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Element Solutions IncESI 49.8/100Thin evidence · provisional58% evidence ASLEEP 17.7/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence 10.6/25 ROCE 2.3% · OPM 13.3% 76% evidence 8.8/20 P/E 64.5× · PEG — 15% evidence 12.7/20 RS sector 6.6% · RS bench 8.2% · 1Y 62.7%7 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 10.6 + 8.8 + 12.7 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Linde plcLIN 47.5/100Thin evidence · provisional58% evidence ASLEEP 18.8/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence 14.3/25 ROCE 3.6% · OPM 27.8% 76% evidence 9.7/20 P/E 33.5× · PEG — 15% evidence 4.7/20 RS sector -10.3% · RS bench -8.3% · 1Y 2.6%0 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 14.3 + 9.7 + 4.7 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Ecolab Inc.ECL 46.7/100Thin evidence · provisional58% evidence TURNING 17.0/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence 12.9/25 ROCE 3.5% · OPM 15.3% 76% evidence 9.5/20 P/E 37.4× · PEG — 15% evidence 7.3/20 RS sector -9% · RS bench -6.6% · 1Y 3.8%1 of 12 weeks ahead 100% evidence
Exact sum: 17 + 12.9 + 9.5 + 7.3 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Cabot CorporationCBT 46.3/100Mixed-negative evidence81% evidence ASLEEP 8.9/35 Revenue -8.5% · PAT -31.2% · OPM change -3 pp 83% evidence 13.3/25 ROCE 4.5% · OPM 14.3% 76% evidence 16.5/20 P/E 14.2× · PEG 0.18 65% evidence 7.6/20 RS sector -5.2% · RS bench -3.1% · 1Y 5%8 of 12 weeks ahead 100% evidence
Exact sum: 8.9 + 13.3 + 16.5 + 7.6 = 46.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
20Air Products and Chemicals, Inc.APD 43.7/100Thin evidence · provisional58% evidence BASING 17.0/35 Revenue — · PAT — · OPM change 103.5 pp 45% evidence 9.5/25 ROCE -5.8% · OPM 23.7% 76% evidence 10.1/20 P/E 30.7× · PEG — 15% evidence 7.1/20 RS sector -7% · RS bench -4.9% · 1Y 2.1%0 of 12 weeks ahead 100% evidence
Exact sum: 17 + 9.5 + 10.1 + 7.1 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Calumet, Inc.CLMT 41.5/100Mixed-negative evidence64% evidence BREAKING OUT 9.4/35 Revenue -0.1% · PAT — · OPM change -11.7 pp 62% evidence 3.0/25 ROCE -9.1% · OPM -16.6% 76% evidence 10.3/20 P/E 30.3× · PEG — 15% evidence 18.8/20 RS sector 40.5% · RS bench 42% · 1Y 189.2%9 of 12 weeks ahead 100% evidence
Exact sum: 9.4 + 3 + 10.3 + 18.8 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 42%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
22Perimeter Solutions, Inc.PRM 40.4/100Thin evidence · provisional58% evidence FADING 10.0/35 Revenue — · PAT — · OPM change -50 pp 45% evidence 7.5/25 ROCE -7.6% · OPM 58% 76% evidence 9.0/20 P/E 53.3× · PEG — 15% evidence 13.9/20 RS sector 7.8% · RS bench 10.3% · 1Y 84.7%10 of 12 weeks ahead 100% evidence
Exact sum: 10 + 7.5 + 9 + 13.9 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23DuPont de Nemours, Inc.DD 38.9/100Mixed-negative evidence81% evidence BASING 22.2/35 Revenue 4% · PAT 40.7% · OPM change 5.2 pp 83% evidence 7.5/25 ROCE 0.7% · OPM 11.1% 76% evidence 4.3/20 P/E 45.4× · PEG 4.12 65% evidence 4.9/20 RS sector -21.8% · RS bench -19.3% · 1Y -32.4%0 of 12 weeks ahead 100% evidence
Exact sum: 22.2 + 7.5 + 4.3 + 4.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Albemarle CorporationALB 38.3/100Thin evidence · provisional53% evidence ASLEEP 20.0/35 Revenue — · PAT — · OPM change 14.5 pp 32% evidence 9.2/25 ROCE 1.6% · OPM 16.3% 76% evidence 9.1/20 P/E 47.9× · PEG — 15% evidence 0.0/20 RS sector -22.9% · RS bench -21.8% · 1Y 60.1%0 of 12 weeks ahead 100% evidence
Exact sum: 20 + 9.2 + 9.1 + 0 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25Hawkins, Inc.HWKN 37.8/100Thin evidence · provisional58% evidence ASLEEP 14.8/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence 12.7/25 ROCE 4.4% · OPM 8.8% 76% evidence 9.4/20 P/E 41.9× · PEG — 15% evidence 0.9/20 RS sector -22.8% · RS bench -20.8% · 1Y -24.6%1 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 12.7 + 9.4 + 0.9 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26LyondellBasell Industries N.V.LYB 33.4/100Adverse evidence71% evidence ASLEEP 13.1/35 Revenue -9.4% · PAT -164.8% · OPM change 1.8 pp 83% evidence 6.5/25 ROCE 0.9% · OPM 3.3% 76% evidence 8.6/20 P/E 76.1× · PEG — 15% evidence 5.2/20 RS sector -5.6% · RS bench -4.2% · 1Y 24.6%2 of 12 weeks ahead 100% evidence
Exact sum: 13.1 + 6.5 + 8.6 + 5.2 = 33.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27The Chemours CompanyCC 28.8/100Adverse evidence64% evidence ASLEEP 12.7/35 Revenue 0.6% · PAT -3836.4% · OPM change -2 pp 62% evidence 4.4/25 ROCE 0.5% · OPM 1.9% 76% evidence 8.5/20 P/E 225.5× · PEG — 15% evidence 3.2/20 RS sector -7.7% · RS bench -6.6% · 1Y 47.1%5 of 12 weeks ahead 100% evidence
Exact sum: 12.7 + 4.4 + 8.5 + 3.2 = 28.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Westlake CorporationWLK 26.1/100Adverse evidence64% evidence BASING 9.8/35 Revenue -8.6% · PAT -473.1% · OPM change -5.4 pp 62% evidence 4.7/25 ROCE -1% · OPM -6.5% 76% evidence 9.6/20 P/E 33.6× · PEG — 15% evidence 2.0/20 RS sector -17.5% · RS bench -16.2% · 1Y 2.1%0 of 12 weeks ahead 100% evidence
Exact sum: 9.8 + 4.7 + 9.6 + 2 = 26.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Solstice Advanced Materials, Inc.SOLS 46.2/100Thin evidence · provisional36% evidence ASLEEP 12.4/35 Revenue — · PAT — · OPM change -4.5 pp 39% evidence 15.1/25 ROCE 9.6% · OPM 16.5% 76% evidence 8.7/20 P/E 67.2× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —1 of 12 weeks ahead 0% evidence
Exact sum: 12.4 + 15.1 + 8.7 + 10 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is H.B. Fuller Company's stock price today?

H.B. Fuller Company trades at $58.9, +5.9% over the past year. The company is valued at $3.0 B. The stock sits at 53% of its 52-week range of $49–$67, −2.0% versus its 200-day average. On the tape, the price is building a base, 6 weeks in. — as of 5 August 2026.

What were H.B. Fuller Company's latest quarterly results?

H.B. Fuller Company reported revenue of $0.9 B and net profit of $0.1 B for the May 26 quarter. Revenue rose 5.6% and profit rose 75.0% year on year. Earnings per share were $1.23. The operating margin was 12.6%, 1.5 pp higher than a year earlier. — as of 5 August 2026.

What is H.B. Fuller Company's revenue?

H.B. Fuller Company reported revenue of $0.9 B in the May 26 quarter, +5.6% year on year. For the full FY25 fiscal year, revenue was $3.5 B (−2.8%). Over the last 4 years revenue compounded at 1.4% a year. — as of 5 August 2026.

What is H.B. Fuller Company's profit?

H.B. Fuller Company earned $0.1 B of net profit in the May 26 quarter, +75.0% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $0.1 B. The operating margin ran 12.6% in the latest quarter. — as of 5 August 2026.

What is H.B. Fuller Company's market cap?

H.B. Fuller Company's market capitalisation is $3.0 B at a stock price of $58.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is H.B. Fuller Company's P/E ratio?

H.B. Fuller Company trades at a P/E of 17.5×, at the 3rd percentile of its own 4-year range, against a long-run median of 25.0×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does H.B. Fuller Company pay a dividend?

Yes — H.B. Fuller Company declared $0.24 per share for May 26, and $0.95 per share across the last four reported quarters. The latest quarter is up 4.3% on the same quarter a year earlier. — as of 5 August 2026.

What is H.B. Fuller Company's dividend per share?

H.B. Fuller Company's most recently declared dividend is $0.24 per share for May 26, giving $0.95 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is H.B. Fuller Company's dividend yield?

H.B. Fuller Company's trailing dividend yield is 1.61%: $0.95 declared per share across the last four reported quarters, against a share price of $58.9. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

Is H.B. Fuller Company overvalued?

On its own history, H.B. Fuller Company looks cheap against its own history: its P/E of 17.5× has been cheaper only 3% of the time in 4 years (long-run median 25.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.

Is H.B. Fuller Company growing?

Yes — H.B. Fuller Company is growing: latest-quarter revenue +5.6% year on year, profit +75.0%, and the margin +1.5 pp at 12.6%. The 4-year compound rates are 1.4% (revenue) and −1.6% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is H.B. Fuller Company performing?

H.B. Fuller Company is building a base, 6 weeks in. Its latest quarter's revenue rose 5.6% and profit rose 75.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is H.B. Fuller Company in?

Improving — profit growth bottomed 3 quarters ago at −41.2% and has held its recovery at +90.0%, ROCE holding at 8.5%. The read comes from the last 12 quarters of growth (revenue growth −0.8% latest, profit growth +90.0% latest, eps growth +82.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is H.B. Fuller Company in an uptrend?

No — the price is building a base (week 6 of stage 1), trading −2.0% versus its 200-day average and at 53% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is H.B. Fuller Company beating the market?

Not lately — on a trailing-13-week view H.B. Fuller Company is currently behind the S&P 500 (7 weeks and counting; last ahead the week of 2026-06-18), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +32% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will H.B. Fuller Company's stock price go up?

This page publishes no price forecast for H.B. Fuller Company. What it measures instead: the stock price is $58.9, the price is building a base 6 weeks in. Its P/E of 17.5× sits at the 3rd percentile of its own 4-year range. — as of 5 August 2026.

Is the market betting against H.B. Fuller Company?

Somewhat — short interest is 4.5% of H.B. Fuller Company's tradable float, about 2.3 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does H.B. Fuller Company have too much debt?

It carries real leverage — H.B. Fuller Company's debt-to-equity is 1.06. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is H.B. Fuller Company's capex?

H.B. Fuller Company spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 5 August 2026.

What is H.B. Fuller Company's cash flow?

H.B. Fuller Company generated $0.3 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is H.B. Fuller Company's profit real cash?

Yes — over the last 3 fiscal years, 224% of H.B. Fuller Company's reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is H.B. Fuller Company?

On the balance sheet, the Z-score reads 2.21 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.

Where is H.B. Fuller Company in its business cycle?

H.B. Fuller Company's FY25 operating margin was 10.4%, against a 5-year band of 7.6%–10.4%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 12.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the H.B. Fuller Company story?

Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is H.B. Fuller Company a stock worth studying right now?

This is not investment advice. The machine read: H.B. Fuller Company is coiled. The quarters are improving, yet the P/E sits at the 3rd percentile of its own 4-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI